Serum Tissue Inhibitor of Metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) Levels in Colorectal Cancer Patients: Associations with Clinicopathological Variables and Patient Survival
Free accessResearch articleFirst published online October, 2009
Serum Tissue Inhibitor of Metalloproteinase 1 and 2 (TIMP-1 and TIMP-2) Levels in Colorectal Cancer Patients: Associations with Clinicopathological Variables and Patient Survival
Tissue inhibitors of metalloproteinases (TIMPs) appear to affect many aspects of cancer biology, playing a crucial role in cell signaling by regulating cell growth, apoptosis, invasion, metastasis, angiogenesis, and genomic instability. The aim of the present study was to elucidate the diagnostic and prognostic utility of TIMP-1 and TIMP-2 in patients with colon cancer. Serum TIMP-1 and TIMP-2 concentrations were quantified using an enzyme-linked immunosorbent assay in 97 colon cancer patients. Elevated serum TIMP-1 levels were found in patients with advanced disease stage (p=0.0512) and poorly differentiated histopathological tumor grade (p=0.0059). Patients with increased TIMP-1 levels had shorter overall survival times (log-rank test, p=0.0143). Multivariate analysis also identified TIMP-1 as an independent prognostic factor (Cox regression analysis, p=0.0149). Serum TIMP-2 levels were not significantly associated with disease stage, histopathological grade or survival. In the subgroup of patients with well and moderately differentiated tumors, TIMP-1 and TIMP-2 were identified as independent prognostic factors (Cox regression analysis, p=0.0379 and p=0.0451, respectively). In conclusion, assessment of serum TIMP-1 can be considered a useful biomarker in colon cancer, whereas TIMP-2 appears to be of limited value.
JiangY., GoldbergI.D., ShiY.E.. Complex role of tissue inhibitors of metalloproteinases in cancer.Oncogene2002; 21: 2245–52.
4.
Alo-AhoR., KahariV.M.. Colagenases in cancer.Biochimie2005; 87: 273–86.
5.
Stetler-StevensonW.G.. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities.Sci Signal2008; 1: re6.
6.
SørensenN.M., SørensenI.V., WürtzSø. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment.Scand J Gastroenterol2008; 43: 774–86.
7.
ChircoR., LiuxW, JungK.K., KimHr. Novel functions of TIMPs in cell signaling.Cancer Metastasis rev2006; 25: 99–113.
8.
MylonaE., MagkouC., GiannopoulouI.. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome.Breast Cancer Res2006; 8: r57.
9.
MinoN., TakenakaK., SonobeM.. Expression of tissue inhibitor of metalloproteinase-3 (TIMP-3) and its prognostic significance in resected non-small cell lung cancer.J Surg Oncol2007; 95: 250–7.
10.
HilskaM., robertsP.J., CollanY.U.. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.Int J Cancer2007; 121: 714–23.
11.
BrancaM., CiottiM., GiorgiC..; HPV-PathogenISS Study Group. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN.Anticancer Res2006; 26: 1543–56.
12.
SharmaR., ChattopadhyayT.K., MathurM., RalhanR.. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer.Oncology2004; 67: 300–9.
13.
GraesslinO., CortezA., FauvetR., LorenzatoM., BirembautP., DaraïE.. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study.Ann Oncol2006; 7: 637–45.
14.
GakiopoulouH., NakopoulouL., SiatelisA.. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas.Clin Cancer Res2003; 9: 5573–81.
15.
SørensenN.M., SchrohlA.S., JensenV., ChristensenI.J., NielsenH.J., BrünnerN.. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.Scand J Gastroenterol2008; 43: 186–91.
16.
SchrohlA.S., MuellerV., ChristensenI.J., PantelK., ThomssenC., BruennerN.. A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.Tumour Biol2008; 29: 181–7.
17.
YlisirniöS., HöyhtyäM., MäkitaroR.. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.Clin Cancer Res2001; 7: 1633–7.
18.
WangC.S., WuT.L., TsaoK.C., SunC.F.. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.Ann Clin Lab Sci2006; 36: 23–30.
19.
HonkavuoriM., Talvensaari-MattilaA., PuistolaU., Turpeenniemi-HujanenT., SantalaM.. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.Anticancer Res2008; 28: 2715–9.
20.
RuokolainenH., PääkköP., Turpeenniemi-HujanenT.. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.Clin Cancer Res2005; 11: 3257–64.
21.
MäättaM., Talvensaari-MattilaA., Turpeenniemi-HujanenT., SantalaM.. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.Anticancer Res2007; 27: 2753–8.
22.
VasalaK., Turpeenniemi-HujanenT.. Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2: TIMP-2) as prognostic markers in bladder cancer.Clin Biochem2007; 40: 640–4.
JooY.E., SeoK.S., KimJ.. role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma.J Korean Med Sci1999; 14: 417–23.
25.
SchwandnerO., SchlampA., BrollR., BruchH.P.. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.Int J Colorectal Dis2007; 22: 127–36.
26.
Holten-AndersenM.N., StephensR.W., NielsenH.J.. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.Clin Cancer Res2000; 6: 4292–9.
27.
WaasE.T., HendriksT., LommeR.M., WobbesT.. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients.Dis Colon Rectum2005; 48: 700–10.
28.
Holten-AndersenM.N., NielsenH.J., SørensenS., JensenV., BrünnerN., ChristensenI.J.. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.Eur J Cancer2006; 42: 1889–96.
29.
YukawaN., YoshikawaT., AkaikeM.. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer.Oncology2007; 72: 205–8.
30.
SørensenN.M., ByströmP., ChristensenI.J.. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.Clin Cancer Res2007; 13: 4117–22.
31.
ObergA., HöyhtyäM., TavelinB., StenlingR., LindmarkG.. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.Anticancer Res2000; 20: 1085–91.
32.
IshidaH., MurataN., HayashiY., TadaM., HashimotoD.. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients.Surg Today2003; 33: 885–92.
33.
HankeB., WeinA., MartusP.. Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy.Br J Cancer2003; 88: 1248–50.
34.
LarsenM.B., StephensR.W., BrünnerN.. Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.Scand J Immunol2005; 61: 449–60.
35.
GreenF.L., PageD.L., FlemingI.D., FritzA., BalchC.M., HallerD.G., MorrowM., eds. Cancer Staging Manual.6th ed.New York, NY: Springer Verlag, 2002.
36.
Holten-AndersenM.N., ChristensenI.J., NielsenH.J.. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer.Clin Cancer Res2002; 8: 156–64.
37.
BakerE.A., BerginF.G., LeaperD.J.. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.Br J Surg2000; 87: 1215–21.
38.
MurashigeM., MiyaharaM., ShiraishiN., SaitoT., KohnoK., KobayashiM.. Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors.Jpn J Clin Oncol1996; 26: 303–9.
39.
rocaF., MauroL.V., MorandiA.. Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma.J Surg Oncol2006; 93: 151–60.
40.
NielsenH.J., BrünnerN., FrederiksenC..; Danish-Australian Endoscopy Study Group on Colorectal Cancer Detection; Danish Colorectal Cancer Cooperative Group. Plasma tissue inhibitor of metalloproteinases-1 (TIMP-1): a novel biological marker in the detection of primary colorectal cancer. Protocol outlines of the Danish-Australian Endoscopy Study Group on Colorectal Cancer Detection.Scand J Gastroenterol2008; 43: 242–8.
41.
FrederiksenC.B., LomholtA.F., LottenburgerT.. Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1.Int J Biol Markers2008; 23: 42–7.
